MSA symposium summary, Summer 2026 - Ataxia UK

MSA symposium summary, Summer 2026

Ataxia UK supports people living with a type of MSA called MSA-C (Multiple System Atrophy – Cerebellar) as people living with MSA-C can have cerebellar ataxia. MSA also has a dedicated charity called the MSA Trust.  

On 18 May 2026, our Science communications intern, Eliana, attended the fourth annual MSA symposium hosted by the UCL Queen Square Institute for Neurology in partnership with the MSA Trust.  

The symposium was attended by over 150 people including patient advocates, researchers, healthcare professionals and industry partners. The programme was packed full of fascinating talks from internationally renowned MSA experts and covered research, clinical and pharmaceutical updates.  

From a clinical perspective, Prof Alessandra Fanciulli talked about the experience and management of pain for people living with MSA and spoke about her ongoing clinical trial, based in Innsbruck only, which aims to evaluate the effects of a personalised symptomatic treatment plan for people living with MSA. Read more about the trial here. Prof Valeria Iodice spoke about the real-world impact of neurogenic orthostatic hypotension (a drop in blood pressure when one stands which can make them feel dizzy or faint) in MSA which she concludes is under-recognised and undertreated and that there is leverage here for clinical trials. Emma Rushton, Director of Information and Services at the MSA Trust highlighted the importance of patient engagement in research. Dr David Oliver, Palliative Care Consultant, talked about the important role of palliative care for people living with MSA. 

From a research perspective, we heard about developments in the understanding of the underlying biology of MSA, the use of MSA animal models to support ongoing research including using these models to test disease-modifying therapies, and the emerging role of biomarkers to aid in diagnosis of MSA. A number of investigational treatments and clinical trials were highlighted including:  

  • HORIZON (Ionis pharmaceuticals) – a Phase 1, randomised, blinded, placebo-controlled, multiple-ascending dose study to evaluate the safety and tolerability of multiple doses of investigational drug ION464 administered via intrathecal injection and in participants with MSA. ION464 is an anti-sense oligonucleotide (ASO). ASOs target the mutated gene, to prevent it from producing the protein which ultimately causes the condition, with the aim of slowing or halting disease progression. Intrathecal is a route of administering a drug by injecting it into the spinal canal. It works by reducing the aggregation of harmful proteins that cause MSA. This trial is currently recruiting in England with sites in Salford, Southampton, London and Oxford. Find out more about the trial here. 
  • TOPAS-MSA (TEVA pharmaceuticals)– a multi-centre, double blind, randomised, placebo-controlled, parallel group Phase 2 trial evaluating the efficacy of oral TEV-56286 (Emrusolmin) for adults with MSA. Emrusolmin works by stopping the development of harmful protein aggregates that cause MSA. Recruitment is ongoing but there are no trial sites in the UK. Read more here. 
  • Alterity Therapeutics investigational oral drug, ATH3434, is designed to reduce iron accumulation and stop harmful protein aggregation that can damage neurons and cause MSA.  We reported positive data from the placebo-controlled Phase 2 trial of ATH434. There is ongoing post-trial access to the drug for people who participated in either this trial or Alterity Therapeutics’ Phase 2 open-label trial of the drug, and who may benefit from it according to their treating doctor. Alterity Therapeutics are planning a Phase 3 trial of ATH434 which they anticipate will start at the end of 2026 or early 2027. Read their press release about this here. 

Subscribe To Our Newsletter

fundraise image

FUNDRAISE FOR US

Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image

DONATE

To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image

VOLUNTEER WITH US

Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Scroll to Top